Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rubella (German Measles) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) - Pipeline Review, H2 2016, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape. Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 2, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Rubella (German Measles). Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Rubella (German Measles) Overview 6 Therapeutics Development 7 Pipeline Products for Rubella (German Measles) - Overview 7 Pipeline Products for Rubella (German Measles) - Comparative Analysis 8 Rubella (German Measles) - Therapeutics under Development by Companies 9 Rubella (German Measles) - Therapeutics under Investigation by Universities/Institutes 10 Rubella (German Measles) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Rubella (German Measles) - Products under Development by Companies 15 Rubella (German Measles) - Products under Investigation by Universities/Institutes 16 Rubella (German Measles) - Companies Involved in Therapeutics Development 17 Beijing Minhai Biotechnology Co., Ltd 17 Beijing Tiantan Biological Products Co., Ltd. 18 Biological E. Limited 19 Daiichi Sankyo Company, Limited 20 GlaxoSmithKline Plc 21 Indian Immunologicals Limited 22 Prometheon Pharma, LLC 23 Sinovac Biotech Ltd. 24 Zydus Cadila Healthcare Limited 25 Rubella (German Measles) - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 (measles + mumps + rubella + varicella) vaccine - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 (measles + mumps + rubella + varicella) vaccine - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 (measles + mumps + rubella) vaccine - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 (measles + mumps + rubella) vaccine - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 (measles + mumps + rubella) vaccine - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 (measles + rubella + varicella) vaccine - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 (measles + rubella) vaccine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 (measles + rubella) vaccine - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 rubella vaccine - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 VN-0102 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Rubella (German Measles) - Dormant Projects 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables Number of Products under Development for Rubella (German Measles), H2 2016 7 Number of Products under Development for Rubella (German Measles) - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Comparative Analysis by Unknown Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 l 16 Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 17 Rubella (German Measles) - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016 18 Rubella (German Measles) - Pipeline by Biological E. Limited, H2 2016 19 Rubella (German Measles) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 20 Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H2 2016 21 Rubella (German Measles) - Pipeline by Indian Immunologicals Limited, H2 2016 22 Rubella (German Measles) - Pipeline by Prometheon Pharma, LLC, H2 2016 23 Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd., H2 2016 24 Rubella (German Measles) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 25 Assessment by Monotherapy Products, H2 2016 26 Assessment by Combination Products, H2 2016 27 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 31 Rubella (German Measles) - Dormant Projects, H2 2016 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.